The Angiotensin II type 1 receptor blocker candesartan suppresses proliferation and fibrosis in gastric cancer

Cancer Letters

Volumn 355, Issue 1, 2014, Pages 46-53

  Okazaki, Mitsuyoshi ^a   Fushida, Sachio ^a   Harada, Shinichi ^b   Tsukada, Tomoya ^a   Kinoshita, Jun ^a   Oyama, Katsunobu ^a   Tajima, Hidehiro ^a   Ninomiya, Itasu ^a   Fujimura, Takashi ^a   Ohta, Tetsuo ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II; Fibrosis; Gastric cancer; Peritoneal dissemination; TGF

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; CANDESARTAN; TELMISARTAN; TRANSFORMING GROWTH FACTOR BETA1; AGTR1 PROTEIN, HUMAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE; TGFB1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFIBROTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FIBROSIS; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; MESOTHELIUM CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STOMACH CANCER; STROMAL FIBROSIS; ANIMAL; BAGG ALBINO MOUSE; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; METABOLISM; NUDE MOUSE; OMENTUM; PATHOLOGY; STOMACH NEOPLASMS; STROMA CELL; TIME; TUMOR CELL LINE; TUMOR VOLUME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FIBROSIS; HUMANS; MICE, INBRED BALB C; MICE, NUDE; OMENTUM; RECEPTOR, ANGIOTENSIN, TYPE 1; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; STROMAL CELLS; TETRAZOLES; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907972416     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.09.019     Document Type: Article

References (57)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin 2011, 14:69-90.
2. Yamazaki H., Oshima A., Murakami R., Endoh S., Ubukata T. A long-term follow-up study of patients with gastric cancer detected by mass screening. Cancer 1989, 63:613-617.
3. Chen C.Y., Wu C.W., Lo S.S., Hsieh M.C., Lui W.Y., Shen K.H. Peritoneal carcinomatosis and lymph node metastasis are prognostic indicators in patients with Borrmann type IV gastric carcinoma. Hepatogastroenterology 2002, 49:874-877.
4. Maruyama K., Kaminishi M., Hayashi K., Isobe Y., Honda I., Katai H., et al. Gastric cancer treated in 1991 in Japan: data analysis of nationwide registry. Gastric Cancer 2006, 9:51-66.
5. Sadeghi B., Arvieux C., Glehen O., Beaujard A.C., Rivoire M., Baulieux J., et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000, 88:358-363.
6. Koizumi W., Narahara H., Hara T., Takagane A., Akiya T., Takagi M., et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008, 9:215-221.
7. Fushida S., Kinoshita J., Yagi Y., Funaki H., Kinami S., Ninomiya I., et al. Dual anti-cancer effects of weekly intraperitoneal docetaxel in treatment of advanced gastric cancer patients with peritoneal carcinomatosis: a feasibility and pharmacokinetic study. Oncol. Rep 2008, 19:1305-1310.
8. Shirao K., Boku N., Yamada Y., Yamaguchi K., Doi T., Goto M., et al. Randomized phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). Jpn. J. Clin. Oncol 2013, 43:972-980.
9. Fushida S., Kinoshita J., Kaji M., Hirono Y., Goda F., Yagi Y., et al. Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis. Cancer Chemother. Pharmacol 2013, 71:1265-1272.
10. Sachio F., Katsunobu O., Jun K., Tomoya T., Kouichi O., Hidehiro T., et al. Intraperitoneal chemotherapy as a multimodal treatment for gastric cancer patients with peritoneal metastasis. J. Cancer Ther 2013, 4:6-15.
11. Otsuji E., Kuriu Y., Okamoto K., Ochiai T., Ichikawa D., Hagiwara A., et al. Outcome of surgical treatment for patients with scirrhous carcinoma of the stomach. Am. J. Surg 2004, 188:327-332.
12. Yashiro M., Chung Y.S., Nishimura S., Inoue T., Sowa M. Fibrosis in the peritoneum induced by scirrhous gastric cancer cells may act as "soil" for peritoneal dissemination. Cancer 1996, 77:1668-1675.
13. Buckley S.T., Medina C., Ehrhardt C. Differential susceptibility to epithelial-mesenchymal transition (EMT) of alveolar, bronchial and intestinal epithelial cells in vitro and the effect of angiotensin II receptor inhibition. Cell Tissue Res 2010, 342:39-51.
14. Xu J., Lamouille S., Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res 2009, 19:156-172.
15. Kalluri R., Neilson E.G. Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Invest 2003, 112:1776-1784.
16. Massagué J. TGFbeta in cancer. Cell 2008, 134:215-230.
17. Shinto O., Yashiro M., Kawajiri H., Shimizu K., Shimizu T., Miwa A., et al. Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells. Br. J. Cancer 2010, 102:844-851.
18. Maehara Y., Kakeji Y., Kabashima A., Emi Y., Watanabe A., Akazawa K., et al. Role of transforming growth factor-beta 1 in invasion and metastasis in gastric carcinoma. J. Clin. Oncol 1999, 17:607-614.
19. Saito H., Tsujitani S., Oka S., Kondo A., Ikeguchi M., Maeta M., et al. An elevated serum level of transforming growth factor-beta 1 (TGF-beta 1) significantly correlated with lymph node metastasis and poor prognosis in patients with gastric carcinoma. Anticancer Res 2000, 20:4489-4493.
20. Hawinkels L.J., Verspaget H.W., van Duijn W., van der Zon J.M., Zuidwijk K., Kubben F.J., et al. Tissue level, activation and cellular localisation of TGF-beta1 and association with survival in gastric cancer patients. Br. J. Cancer 2007, 97:398-404.
21. Zeisberg E.M., Potenta S., Xie L., Zeisberg M., Kalluri R. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res 2007, 67:10123-10128.
22. Pietras K., Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp. Cell Res 2010, 316:1324-1331.
23. Durning P., Schor S.L., Sellwood R.A. Fibroblasts from patients with breast cancer show abnormal migratory behaviour in vitro. Lancet 1984, 2:890-892.
24. Yashiro M., Chung Y.S., Sowa M. Role of orthotopic fibroblasts in the development of scirrhous gastric carcinoma. Jpn J. Cancer Res 1994, 85:883-886.
25. Tsukada T., Fushida S., Harada S., Yagi Y., Kinoshita J., Oyama K., et al. The role of human peritoneal mesothelial cells in the fibrosis and progression of gastric cancer. Int. J. Oncol 2012, 41:476-482.
26. Lv Z.D., Na D., Ma X.Y., Zhao C., Zhao W.J., Xu H.M. Human peritoneal mesothelial cell transformation into myofibroblasts in response to TGF-ß1 in vitro. Int. J. Mol. Med 2011, 27:187-193.
27. Pinto M.P., Badtke M.M., Dudevoir M.L., Harrell J.C., Jacobsen B.M., Horwitz K.B. Vascular endothelial growth factor secreted by activated stroma enhances angiogenesis and hormone-independent growth of estrogen receptor-positive breast cancer. Cancer Res 2010, 70:2655-2664.
28. Tyan S.W., Kuo W.H., Huang C.K., Pan C.C., Shew J.Y., Chang K.J., et al. Breast cancer cells induce cancer-associated fibroblasts to secrete hepatocyte growth factor to enhance breast tumorigenesis. PLoS ONE 2011, 6:e15313.
29. Fushida S., Yonemura Y., Urano T., Yamaguchi A., Miyazaki I., Nakamura T., et al. Expression of hepatocyte growth factor(hgf) and C-met gene in human gastric-cancer cell-lines. Int. J. Oncol 1993, 3:1067-1070.
30. Kinoshita J., Fushida S., Harada S., Yagi Y., Fujita H., Kinami S., et al. Local angiotensin II-generation in human gastric cancer: correlation with tumor progression through the activation of ERK1/2, NF-kappaB and survivin. Int. J. Oncol 2009, 34:1573-1582.
31. Okamoto K., Tajima H., Ohta T., Nakanuma S., Hayashi H., Nakagawara H., et al. Angiotensin II induces tumor progression and fibrosis in intrahepatic cholangiocarcinoma through an interaction with hepatic stellate cells. Int. J. Oncol 2010, 37:1251-1259.
32. Du N., Feng J., Hu L.J., Sun X., Sun H.B., Zhao Y., et al. Angiotensin II receptor type 1 blockers suppress the cell proliferation effects of angiotensin II in breast cancer cells by inhibiting AT1R signaling. Oncol. Rep 2012, 27:1893-1903.
33. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., et al. RENAAL study investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med 2001, 345:861-869.
34. Casas J.P., Chua W., Loukogeorgakis S., Vallance P., Smeeth L., Hingorani A.D., et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005, 366:2026-2033.
35. Mann J.F., Schmieder R.E., McQueen M., Dyal L., Schumacher H., Pogue J., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547-553.
36. Brooke B.S., Habashi J.P., Judge D.P., Patel N., Loeys B., Dietz H.C. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N. Eng. J. Med 2008, 358:2787-2795.
37. Yung S., Li F.K., Chan T.M. Peritoneal mesothelial cell culture and biology. Perit. Dial. Int 2006, 26:162-173.
38. Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activi- ty. Hypertension 2004, 43:993-1002.
39. Schupp M., Janke J., Clasen R., Unger T., Kintscher U. Angiotensin type 1 receptor block- ers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004, 109:2054-2057.
40. Peach M.J. Renin-angiotensin system: biochemistry and mechanisms of action. Physiol. Rev 1977, 57:313-370.
41. Escobar E., Rodríguez-Reyna T.S., Arrieta O., Sotelo J. Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer. Curr. Vasc. Pharmacol 2004, 4:385-399.
42. Arakawa K., Maruta H. Ability of kallikrein to generate angiotensin II-like pressor substance and a proposed 'kinin-tensin enzyme system. Nature 1980, 25:705-706.
43. Amaya K., Ohta T., Kitagawa H., Kayahara M., Takamura H., Fujimura T., et al. Angiotensin II activates MAP kinase and NF-kappaB through angiotensin II type I receptor in human pancreatic cancer cells. Int. J. Oncol 2004, 25:849-856.
44. Carl-McGrath S., Ebert M.P., Lendeckel U., Röcken C. Expression of the local angiotensin II system in gastric cancer may facilitate lymphatic invasion and nodal spread. Cancer Biol. Ther 2007, 6:1218-1226.
45. Lever A.F., Hole D.J., Gillis C.R., McCallum I.R., McInnes G.T., MacKinnon P.L., et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?. Lancet 1998, 352:179-184.
46. Brunet A., Roux D., Lenormand P., Dowd S., Keyse S., Pouysségur J. Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J. 1999, 18:664-674.
47. Lee R., Collins T. Nuclear factor-kappaB and cell survival: IAPs call for support. Circ. Res 2001, 88:262-264.
48. Ambrosini G., Adida C., Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med 1997, 3:917-921.
49. Wolf G. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway. Kidney Int 2006, 70:1914-1919.
50. Carvajal G., Rodríguez-Vita J., Rodrigues-Díez R., Sánchez-López E., Rupérez M., Cartier C., et al. Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation. Kidney Int 2008, 74:585-595.
51. Naito T., Masaki T., Nikolic-Paterson D.J., Tanji C., Yorioka N., Kohno N. Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: a mechanism for activation of latent TGF-beta1. Am. J. Physiol. Renal Physiol 2004, 286:F278-F287.
52. Chua C.C., Hamdy R.C., Chua B.H. Regulation of thrombospondin-1 production by angiotensin II in rat heart endothelial cells. Biochim. Biophys. Acta 1997, 1357:209-214.
53. Yonemura Y., Endo Y., Yamaguchi T., Fujimura T., Obata T., Kawamura T., et al. Mechanisms of the formation of the peritoneal dissemination in gastric cancer. Int. J. Oncol 1996, 8:795-802.
54. Lv Z.D., Wang H.B., Dong Q., Kong B., Li J.G., Yang Z.C., et al. Mesothelial cells differentiate into fibroblast-like cells under the scirrhous gastric cancer microenvironment and promote peritoneal carcinomatosis in vitro and in vivo. Mol. Cell. Biochem 2013, 377:177-185.
55. Roberts A.B., Sporn M.B. The transforming growth factor βs. Peptides, Growth Factors and Their Receptors Part I 1990, 419-472. Springer-Verlag, Berlin. M.B. Sporn, A.B. Roberts (Eds.).
56. Naritomi H., Fujita T., Ito S., Ogihara T., Shimada K., Shimamoto K., et al. Efficacy and safety of long-term losartan therapy demonstrated by a prospective observational study in Japanese patients with hypertension: the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study. Hypertens. Res 2008, 31:295-304.
57. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2007, 22:659-661.